{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:32:21Z","timestamp":1780378341226,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Young Scientists","award":["21K15667"],"award-info":[{"award-number":["21K15667"]}]},{"name":"JST PRESTO","award":["JPMJPR21R7"],"award-info":[{"award-number":["JPMJPR21R7"]}]},{"name":"JAID Clinical Research Promotion Grant"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21fk0108621h0001"],"award-info":[{"award-number":["21fk0108621h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In Japan, <jats:italic>Mycobacterium avium<\/jats:italic> complex lung disease (MAC-LD) is the most common in nontuberculous mycobacterial lung disease. Patients often experience adverse events, resulting in the discontinuation of treatment, which causes treatment failure. The JADER (Japanese Adverse Drug Event Report) database is a database of adverse events that allows us to collect real-world data on adverse events. We can collect large-scale data cost-effectively and detect signals of potential adverse events such as reporting odds ratio (ROR) by using spontaneous reporting systems. In this study, we aimed to elucidate the adverse events of clarithromycin (CAM), ethambutol (EB), and rifampicin (RFP) using the JADER database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included cases of MAC-LD between April 2004 and June 2017. We investigated sex, age, and medications that may have caused the adverse events, outcomes, and time of onset. We calculated the safety signal index as the ROR. Time-to-event analysis was performed using the Weibull distribution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The total number of adverse events of CAM, EB, and RFP was 2780, with 806 patients. In the overall adverse events, hematologic and lymphatic disorders were the most common adverse events, with 17.3%, followed by eye disorders (16.6%), and hepatobiliary disorders (14.0%). The outcomes were as follows: recovery, 40.0%; remission, 27.1%; non-recovery, 11.2%; and death, 7.1%. Regarding the most common onset time of CAM, EB, and RFP was within 120\u00a0days at 40%, 181\u2013300\u00a0days at 43.6%, and within 120\u00a0days at 88.5%. For CAM, the RORs of infections and infestations, hepatobiliary system disorders, and immune system disorders were 4.13 (95% confidence interval [CI], 2.3\u20137.44), 2.61 (95% CI, 1.39\u20134.91), and 2.38 (95% CI, 1.04\u20135.44). For EB, the ROR of eye disorders was 215.79 (95% CI, 132.62\u2013351.12). For RFP, the RORs of renal and urinary tract disorders and investigations were 7.03 (95% CI, 3.35\u201314.77) and 6.99 (95% CI, 3.22\u201315.18). The \u03b2 value of EB was 2.07 (95% CI, 1.48\u20132.76), which was classified as a wear-out failure type.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For MAC-LD, the adverse event which has the highest ROR is infections and infestations in CAM, eye disorders in EB, renal and urinary tract disorders in RFP. Adverse events of EB occur after 180\u00a0days, whereas the adverse events of CAM and RFP occur early in the course of treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07568-z","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T07:07:05Z","timestamp":1656486425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system"],"prefix":"10.1186","volume":"22","author":[{"given":"Takuya","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"Namkoong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risako","family":"Takaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Kizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"1","key":"7568_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","volume":"36","author":"DR Prevots","year":"2015","unstructured":"Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13\u201334.","journal-title":"Clin Chest Med"},{"issue":"6","key":"7568_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3201\/eid2206.151086","volume":"22","author":"H Namkoong","year":"2016","unstructured":"Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016;22(6):1116\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"7568_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1513\/AnnalsATS.201607-573OC","volume":"14","author":"K Morimoto","year":"2017","unstructured":"Morimoto K, Hasegawa N, Izumi K, Namkoong H, Uchimura K, Yoshiyama T, et al. A laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013. Ann Am Thorac Soc. 2017;14(1):49\u201356.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"7568_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1513\/AnnalsATS.201303-067OC","volume":"11","author":"K Morimoto","year":"2014","unstructured":"Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014;11(1):1\u20138.","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"7568_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","volume":"105","author":"M Mehta","year":"2011","unstructured":"Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011;105(11):1718\u201325.","journal-title":"Respir Med"},{"key":"7568_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.rmed.2018.10.023","volume":"145","author":"T Asakura","year":"2018","unstructured":"Asakura T, Yamada Y, Suzuki S, Namkoong H, Okamori S, Kusumoto T, et al. Quantitative assessment of erector spinae muscles in patients with Mycobacterium avium complex lung disease. Respir Med. 2018;145:66\u201372.","journal-title":"Respir Med"},{"key":"7568_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.7326\/0003-4819-121-12-199412150-00001","volume":"121","author":"RE Chaisson","year":"1994","unstructured":"Chaisson RE, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Carl Craft J, Sattler FR. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. Ann Intern Med. 1994;121:905\u201311.","journal-title":"Ann Intern Med"},{"key":"7568_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1086\/514116","volume":"176","author":"MP Dube","year":"1997","unstructured":"Dube MP, Torriani FJ, See D, Havlir DV, Kemper CA, Dezfuli MG, Bartok AE, Tilles JG, McCutchan JA. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis. 1997;176:1225\u201332.","journal-title":"J Infect Dis"},{"key":"7568_CR9","first-page":"487","volume":"87","author":"AW Hiraku","year":"2012","unstructured":"Hiraku AW, Seiya UEDA, Chika SATO, Masahiro ABE. A study of adverse drug reactions in the treatment of pulmonary mycobacterium avium complex disease. Kekkaku. 2012;87:487\u201390.","journal-title":"Kekkaku"},{"issue":"12","key":"7568_CR10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.5588\/ijtld.18.0171","volume":"22","author":"Y Kamii","year":"2018","unstructured":"Kamii Y, Nagai H, Kawashima M, Matsuki M, Nagoshi S, Sato A, et al. Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis. 2018;22(12):1505\u201310.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"7568_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1378\/chest.13-2538","volume":"146","author":"RJ Wallace Jr","year":"2014","unstructured":"Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, et al. Macrolide\/Azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146(2):276\u201382.","journal-title":"Chest"},{"issue":"1","key":"7568_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","volume":"191","author":"BH Jeong","year":"2015","unstructured":"Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;191(1):96\u2013103.","journal-title":"Am J Respir Crit Care Med"},{"key":"7568_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.rmed.2017.08.031","volume":"131","author":"S Zweijpfenning","year":"2017","unstructured":"Zweijpfenning S, Kops S, Magis-Escurra C, Boeree MJ, van Ingen J, Hoefsloot W. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. Respir Med. 2017;131:220\u20134.","journal-title":"Respir Med"},{"issue":"9","key":"7568_CR14","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e59","volume":"35","author":"YS Kwon","year":"2020","unstructured":"Kwon YS, Kwon BS, Kim OH, Park YE, Shim TS, Chong YP, et al. Treatment outcomes after discontinuation of ethambutol due to adverse events in Mycobacterium avium complex lung disease. J Korean Med Sci. 2020;35(9): e59.","journal-title":"J Korean Med Sci"},{"issue":"Suppl C","key":"7568_CR15","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","volume":"20","author":"SA Goldman","year":"1998","unstructured":"Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C):C40\u20134.","journal-title":"Clin Ther"},{"key":"7568_CR16","unstructured":"Guidelines for the Conduct of Pharmacoepidemiological Studies in Drug Safety Assessment with Medical Information Databases. Available at https:\/\/www.pmda.go.jp\/files\/000240951.pdf. Accessed 06 Mar 2022"},{"issue":"4","key":"7568_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1\u201336.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"7568_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"LH Shakir","year":"2006","unstructured":"Shakir LH. Under-reporting of adverse drug reactions a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"2","key":"7568_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.resinv.2020.09.010","volume":"59","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Tsuyuguchi K, Yoshida S, Kimura Y, Tsuji T, Minomo S, et al. Resumption\/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen. Respir Investig. 2021;59(2):212\u20137.","journal-title":"Respir Investig"},{"issue":"5","key":"7568_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jiac.2017.01.007","volume":"23","author":"J Kadota","year":"2017","unstructured":"Kadota J, Kurashima A, Suzuki K. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: a nationwide post-marketing study. J Infect Chemother. 2017;23(5):293\u2013300.","journal-title":"J Infect Chemother"},{"key":"7568_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jgar.2020.01.004","volume":"22","author":"YS Kwon","year":"2020","unstructured":"Kwon YS, Han M, Kwon BS, Kim OH, Lee HY, Shim TS, et al. Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: a propensity score analysis. J Glob Antimicrob Resist. 2020;22:106\u201312.","journal-title":"J Glob Antimicrob Resist"},{"issue":"6","key":"7568_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1378\/chest.76.6.782","volume":"76","author":"WW Addington","year":"1979","unstructured":"Addington WW. The side effects and interactions of antituberculosis drugs. Chest. 1979;76(6):782\u20134.","journal-title":"Chest"},{"issue":"3","key":"7568_CR23","first-page":"213","volume":"137","author":"LM Kahana","year":"1987","unstructured":"Kahana LM. Toxic ocular effects of ethambutol. CMAJ. 1987;137(3):213\u20136.","journal-title":"CMAJ"},{"issue":"2","key":"7568_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1749-6632.1966.tb45532.x","volume":"135","author":"JE Leibold","year":"1966","unstructured":"Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci. 1966;135(2):904\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"7568_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.200407-863OC","volume":"172","author":"DE Griffith","year":"2005","unstructured":"Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2005;172(2):250\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"7568_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10792-009-9293-z","volume":"30","author":"AS Katherine","year":"2010","unstructured":"Katherine AS. Risk factors for ethambutol optic toxicity. Int Ophthalmol. 2010;30(1):63\u201372.","journal-title":"Int Ophthalmol"},{"key":"7568_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/ndt\/13.4.924","volume":"13","author":"A Covic","year":"1998","unstructured":"Covic A, Segall L, Stoicescu C, Lungu S, Volovat C, Covic M. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transpl. 1998;13:924\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"7568_CR28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/ajkd.2002.35675","volume":"40","author":"T Muthukumar","year":"2002","unstructured":"Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi MA. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis. 2002;40(4):690\u20136.","journal-title":"Am J Kidney Dis"},{"key":"7568_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/ajkd.1998.v31.pm9428460","volume":"31","author":"AS De Vriese","year":"1998","unstructured":"De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis. 1998;31:108\u201315.","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"7568_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010556","volume":"97","author":"JS Kim","year":"2018","unstructured":"Kim JS, Kim KJ, Choi EY. Minimal change disease related to rifampicin presenting with acute renal failure during treatment for latent tuberculosis infection: a case report. Medicine (Baltimore). 2018;97(22): e10556.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"7568_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/2042098616667704","volume":"7","author":"L Ait Moussa","year":"2016","unstructured":"Ait Moussa L, El Bouazzi O, Serragui S, Soussi Tanani D, Soulaymani A, Soulaymani R. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis. Ther Adv Drug Saf. 2016;7(6):239\u201347.","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"7568_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","volume":"11","author":"S Miwa","year":"2014","unstructured":"Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc. 2014;11(1):23\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"7568_CR33","doi-asserted-by":"crossref","unstructured":"Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22(6).","DOI":"10.1093\/bib\/bbab347"},{"issue":"2","key":"7568_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pds.4944","volume":"29","author":"M Tsuchiya","year":"2020","unstructured":"Tsuchiya M, Obara T, Sakai T, Nomura K, Takamura C, Mano N. Quality evaluation of the Japanese Adverse Drug Event Report database (JADER). Pharmacoepidemiol Drug Saf. 2020;29(2):173\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"7568_CR35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"7568_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota K, Koide D, Hirai T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf. 2004;13(6):387\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"7568_CR37","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/bib\/bbx010","volume":"19","author":"S Vilar","year":"2018","unstructured":"Vilar S, Friedman C, Hripcsak G. Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. Brief Bioinform. 2018;19(5):863\u201377.","journal-title":"Brief Bioinform"},{"key":"7568_CR38","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","volume":"10","author":"Y Noguchi","year":"2019","unstructured":"Noguchi Y, Tachi T, Teramachi H. Review of statistical methodologies for detecting drug\u2013drug interactions using spontaneous reporting systems. Front Pharmacol. 2019;10:1319.","journal-title":"Front Pharmacol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07568-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07568-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07568-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T07:07:38Z","timestamp":1656486458000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07568-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7568"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07568-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"6 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"580"}}